Table 2.
Study outcomes.
| Outcomes | Alteplase Group | Control Group | Binary Logistic Regression Analysis | |
|---|---|---|---|---|
| Unmatched cohort | (n = 51) | (n = 84) | Adjusted OR (95% CI) | P-value |
| Primary outcomes | ||||
| mRS ≤ 1 at 3 months, n (%)† | 28 (54.9) | 40 (47.6) | 0.30 (0.12, 0.74) | 0.009 |
| Early neurological deterioration, n (%)‡ | 8 (15.7) | 27 (32.1) | 2.55 (1.05, 6.16) | 0.038 |
| Secondary and safety outcomes | ||||
| mRS ≤ 2 at 3 months, n (%)† | 40 (78.4) | 62 (73.8) | 0.43 (0.16, 1.12) | 0.084 |
| mRS ≥ 4 at 3 months, n (%)† | 5 (9.8) | 13 (15.5) | 3.14 (0.90, 10.91) | 0.072 |
| Intracranial hemorrhage, n (%) | 2 (3.9)* | 0 | – | – |
| Death, n (%) | 0 | 1 (2.0) | – | – |
| Matched cohort | (n = 42) | (n = 42) | Unadjusted OR (95% CI) | P-value |
| Primary outcomes | ||||
| mRS ≤ 1 at 3 months, n (%) | 28 (66.7) | 14 (33.3) | 0.25 (0.10, 0.62) | 0.003 |
| Early neurological deterioration, n (%) | 5 (11.9) | 13 (31.0) | 3.32 (1.06, 10.37) | 0.039 |
| Secondary and safety outcomes | ||||
| mRS ≤ 2 at 3 months, n (%) | 35 (83.3) | 26 (61.9) | 0.33 (0.12, 0.90) | 0.031 |
| mRS ≥ 4 at 3 months, n (%) | 3 (7.1) | 10 (23.8) | 4.06 (1.03, 16.02) | 0.045 |
| Intracranial hemorrhage, n (%) | 2 (5.0)* | 0 | – | – |
| Death, n (%) | 0 | 1 (2.5) | – | – |
mRS, modified Rankin scale score; OR, odds ratio.
These models were adjusted for baseline NIHSS score and history of ischemic stroke.
‡
Univariate logistic regression analysis was performed due to the failure of fitting a multivariate model adjusted for baseline NIHSS score and history of ischemic stroke.
*
There were two cases (3.9%) of parenchymal hemorrhage type 2 according to the criteria of ECASS II in the alteplase group, one of the two cases had symptomatic intracranial hemorrhage in the infarcted region and left severe disability.